Beam Therapeutics upgraded to Outperform from Market Perform at Leerink

By Yahoo! Finance | Nov 7, 2024 at 06:29 AM EST

Leerink upgraded Beam Therapeutics (BEAM) to Outperform with a price target of $39. The firm was cautious due to safety concerns but now sees potential in BEAM-301 data. They believe in the company's innovative approach to address genetic disorders.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.